GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Down 62.4% in March

GT Biopharma, Inc. (NASDAQ:GTBP) saw a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 94,200 shares, a drop of 62.4% from the February 28th total of 250,300 shares. Based on an average daily trading volume, of 852,200 shares, the short-interest ratio is presently 0.1 days. Approximately 4.2% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on GTBP. Roth Mkm started coverage on GT Biopharma in a research report on Monday, December 2nd. They set a “buy” rating and a $11.00 price target on the stock. Roth Capital raised shares of GT Biopharma to a “strong-buy” rating in a report on Monday, December 2nd.

GT Biopharma Stock Up 2.5 %

Shares of GTBP stock opened at $2.42 on Thursday. The business has a 50 day moving average of $2.29 and a two-hundred day moving average of $2.50. The company has a market cap of $6.14 million, a P/E ratio of -0.35 and a beta of 0.59. GT Biopharma has a 52 week low of $1.72 and a 52 week high of $10.66.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.